PL3124040T3 - IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią - Google Patents
IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapiąInfo
- Publication number
- PL3124040T3 PL3124040T3 PL16188978T PL16188978T PL3124040T3 PL 3124040 T3 PL3124040 T3 PL 3124040T3 PL 16188978 T PL16188978 T PL 16188978T PL 16188978 T PL16188978 T PL 16188978T PL 3124040 T3 PL3124040 T3 PL 3124040T3
- Authority
- PL
- Poland
- Prior art keywords
- chemotherapy
- therapy
- induced neuropathy
- neuropathy
- induced
- Prior art date
Links
- 101150101999 IL6 gene Proteins 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 201000001119 neuropathy Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 208000033808 peripheral neuropathy Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL16167304A IL161673A0 (en) | 2004-04-29 | 2004-04-29 | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| PCT/IL2005/000444 WO2005105135A1 (en) | 2004-04-29 | 2005-04-28 | Il-6 for therapy or prevention of chemotherapy-induced neuropathy |
| EP05737409.2A EP1740200B1 (en) | 2004-04-29 | 2005-04-28 | Il-6 for therapy or prevention of chemotherapy-induced neuropathy |
| EP16188978.7A EP3124040B1 (en) | 2004-04-29 | 2005-04-28 | Il-6 for therapy of chemotherapy-induced neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3124040T3 true PL3124040T3 (pl) | 2020-08-24 |
Family
ID=34074041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16188978T PL3124040T3 (pl) | 2004-04-29 | 2005-04-28 | IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią |
| PL05737409T PL1740200T3 (pl) | 2004-04-29 | 2005-04-28 | IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05737409T PL1740200T3 (pl) | 2004-04-29 | 2005-04-28 | IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7951359B2 (pl) |
| EP (2) | EP3124040B1 (pl) |
| JP (1) | JP2007534746A (pl) |
| AU (1) | AU2005237324A1 (pl) |
| CA (1) | CA2564390A1 (pl) |
| DK (2) | DK3124040T3 (pl) |
| ES (2) | ES2788131T3 (pl) |
| IL (2) | IL161673A0 (pl) |
| NO (1) | NO20065471L (pl) |
| PL (2) | PL3124040T3 (pl) |
| WO (1) | WO2005105135A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL163856A0 (en) | 2004-09-01 | 2005-12-18 | Applied Research Systems | Use of IL-6 in vascular complications |
| US8372389B2 (en) | 2007-11-28 | 2013-02-12 | Hadasit Medical Research Services And Development Ltd. | Methods for the treatment of radiation or chemotherapy-induced tissue damage |
| WO2012037283A2 (en) * | 2010-09-14 | 2012-03-22 | Mount Sinai School Of Medicine | Admimistration of sns neuroprotective agents to promote hematopoietic regeration |
| EP3299032A1 (en) | 2016-09-23 | 2018-03-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Inhibitors of gpr132 for use in preventing and/or treating chemotherapy-induced neuropathic pain |
| WO2019221528A1 (en) * | 2018-05-17 | 2019-11-21 | Helixmith Co., Ltd. | Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy |
| WO2022256688A1 (en) * | 2021-06-04 | 2022-12-08 | Sonnet BioTherapeutics, Inc. | Methods of treating age-related frailty with interleukin-6 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| AU645294B2 (en) | 1989-12-22 | 1994-01-13 | Merck Serono Sa | Endogenous gene expression modification with regulatory element |
| KR100234520B1 (ko) | 1991-01-18 | 1999-12-15 | 그레고리 아보트 | 종양괴사인자 매개병 치료용 의약품 조성물 |
| IT1247484B (it) | 1991-03-22 | 1994-12-17 | Ceinge Societa Consortile A R | Metodo per la preparazione di interleuchina 6 |
| WO1994003492A1 (en) | 1992-08-06 | 1994-02-17 | The University Of Melbourne | Interleukin-6 variants and uses therefor |
| IT1263022B (it) | 1992-11-06 | 1996-07-23 | Angeletti P Ist Richerche Bio | Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica. |
| IT1261787B (it) | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| WO1997016202A1 (en) * | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
| ATE403001T1 (de) * | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
| CA2281493A1 (en) * | 1997-02-20 | 1998-08-27 | David S. Dime | Site-specific drug delivery |
| IT1291932B1 (it) * | 1997-06-20 | 1999-01-21 | Angeletti P Ist Richerche Bio | Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma |
| IL122818A0 (en) | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
| WO2001003737A1 (en) | 1999-07-13 | 2001-01-18 | Bolder Biotechnology Inc. | Immunoglobulin fusion proteins |
| WO2003033015A1 (en) * | 2001-10-11 | 2003-04-24 | Applied Research Systems Ars Holding N.V. | USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| IL163856A0 (en) * | 2004-09-01 | 2005-12-18 | Applied Research Systems | Use of IL-6 in vascular complications |
-
2004
- 2004-04-29 IL IL16167304A patent/IL161673A0/xx unknown
-
2005
- 2005-04-28 DK DK16188978.7T patent/DK3124040T3/da active
- 2005-04-28 ES ES16188978T patent/ES2788131T3/es active Active
- 2005-04-28 AU AU2005237324A patent/AU2005237324A1/en not_active Abandoned
- 2005-04-28 EP EP16188978.7A patent/EP3124040B1/en active Active
- 2005-04-28 PL PL16188978T patent/PL3124040T3/pl unknown
- 2005-04-28 PL PL05737409T patent/PL1740200T3/pl unknown
- 2005-04-28 WO PCT/IL2005/000444 patent/WO2005105135A1/en active Application Filing
- 2005-04-28 JP JP2007510235A patent/JP2007534746A/ja active Pending
- 2005-04-28 DK DK05737409.2T patent/DK1740200T3/en active
- 2005-04-28 ES ES05737409.2T patent/ES2657049T3/es active Active
- 2005-04-28 US US11/587,937 patent/US7951359B2/en active Active
- 2005-04-28 EP EP05737409.2A patent/EP1740200B1/en active Active
- 2005-04-28 CA CA002564390A patent/CA2564390A1/en not_active Abandoned
-
2006
- 2006-10-16 IL IL178636A patent/IL178636A0/en unknown
- 2006-11-28 NO NO20065471A patent/NO20065471L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK3124040T3 (da) | 2020-04-20 |
| WO2005105135A8 (en) | 2006-12-07 |
| US20080193409A1 (en) | 2008-08-14 |
| EP1740200B1 (en) | 2017-11-22 |
| EP3124040A1 (en) | 2017-02-01 |
| JP2007534746A (ja) | 2007-11-29 |
| NO20065471L (no) | 2007-01-09 |
| ES2657049T3 (es) | 2018-03-01 |
| IL178636A0 (en) | 2007-02-11 |
| PL1740200T3 (pl) | 2018-04-30 |
| WO2005105135A1 (en) | 2005-11-10 |
| ES2788131T3 (es) | 2020-10-20 |
| DK1740200T3 (en) | 2018-01-08 |
| CA2564390A1 (en) | 2005-11-10 |
| EP3124040B1 (en) | 2020-02-12 |
| AU2005237324A1 (en) | 2005-11-10 |
| EP1740200A1 (en) | 2007-01-10 |
| IL161673A0 (en) | 2004-09-27 |
| US7951359B2 (en) | 2011-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1753428A4 (en) | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS | |
| EP1799865A4 (en) | PROCESS FOR THE ADMINISTRATION OF ILOPERIDONE | |
| ZA200701281B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| GB0423554D0 (en) | Therapeutic compounds | |
| ZA200609542B (en) | Therapeutic compounds | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| IL183176A0 (en) | Methods for the preparation of sevoflurane | |
| IL182693A0 (en) | Methods of preparing indazole compounds | |
| ZA200702977B (en) | Methods of preparing indazole compounds | |
| EP1789027A4 (en) | Therapeutic Use of Anti- TF Antigen Antibodies | |
| ZA200703695B (en) | Treatment of mastitis with enrofloxacin | |
| PL3124040T3 (pl) | IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią | |
| GB0420424D0 (en) | Therapeutic compounds | |
| HK1155670A1 (en) | Therapeutic use of anti-cs1 antibodies | |
| IL178635A0 (en) | Compositions and methods for therapy of chemotherapy-induced neuropathy | |
| GB0427138D0 (en) | Therapeutic compounds | |
| GB0423767D0 (en) | Therapeutic compounds | |
| GB0417560D0 (en) | Therapeutic compounds | |
| GB0427882D0 (en) | Therapeutic uses for honey | |
| GB0405012D0 (en) | Therapeutic compounds | |
| GB0427841D0 (en) | Therapeutic compounds | |
| GB0427842D0 (en) | Therapeutic compounds | |
| GB0403988D0 (en) | Therapeutic compounds | |
| GB0419718D0 (en) | Therapeutic compounds | |
| GB0407481D0 (en) | Therapeutic compounds |